cindunistat

Cindunistat (SD-6010) is a potent, orally active, and selective inhibitor of inducible nitric oxide synthase (iNOS or NOS2). It acts as a time-dependent and irreversible inhibitor of human iNOS. Cindunistat was developed by Pfizer for the potential treatment of osteoarthritis due to its ability to inhibit NO production and modulate inflammatory processes. In preclinical models, it improved biomarkers related to joint damage and pain behavior. However, in clinical trials for knee osteoarthritis, cindunistat did not demonstrate sustained efficacy in slowing disease progression compared to placebo. Development for this indication has been discontinued[1][2][3][4][6].

Other names

cindunistat hydrochloride maleate